Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
about
Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists.Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity.Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brainThe effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian ratThe serotonergic system in motor and non-motor manifestations of Parkinson's disease.MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.Serotonin innervation of human basal ganglia.The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q30833645-07B25898-4CB0-4FC6-BA9D-33F54AE87B7FQ33687521-D745A0D9-FBA7-4B99-88DF-D14DB376C0DBQ34162681-73F61C32-84A8-45EC-870E-89361CD3E1B3Q35087525-DDAF3D70-74C2-4C25-8698-33BBB7710005Q35324977-43C437DD-257A-4321-8287-795954AA7D32Q36851713-33A185C3-D644-4B0E-BB23-3BE6D52FA7B0Q36852272-9FF4D4E7-2462-40FF-BA2E-80BE208CB55DQ38118061-52710AA9-50B4-4399-846F-EB9D126FB8CDQ39906818-F6D65C44-69B0-4CDB-913E-94BB98C18BE4Q42484813-1A69443E-A45B-49D7-82B0-23CE97EB7EA6Q42647545-E54B5B61-6827-4B0E-81E8-257E756E1600Q48300577-39129977-DAA0-4C4F-90E4-2C97032450E0Q57518128-7AD38258-A7D6-4272-801E-1548CB57112A
P2860
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@en
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@nl
type
label
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@en
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@nl
prefLabel
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@en
Local administration of sarizo ...... esias in 6-OHDA-lesioned rats.
@nl
P2093
P921
P1433
P1476
Local administration of sarizo ...... nesias in 6-OHDA-lesioned rats
@en
P2093
P2860
P2888
P304
P356
10.1007/S00213-008-1452-9
P577
2009-01-22T00:00:00Z